Jill E Chrencik

Dr. Jill E Chrencik


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MJMaru Jaime-Garza
Maru Jaime-Garza
AWAndrew Waight
Andrew Waight
MHManish Hudlikar
Manish Hudlikar
MEMichael J. Eddins
Michael J. Eddins
ERElnaz S. Rasti
Elnaz S. Rasti
CNCameron Noland
Cameron Noland
Background/Objectives: Antibody–Drug Conjugates (ADCs) have rapidly evolved from early, rudimentary conjugates to highly targeted and precisely engineered molecules. Despite notable clinical successes, ADCs continue to face significant challenges, including aggregation and high hydrophobicity driven by high drug-to-antibody ratios (DARs), premature payload release, dose-limiting toxicities, and suboptimal pharmacokinetics. While site-specific linker–payload conjugation has improved ADC homogeneity and stability, the structural basis of antibody–linker interactions at specific sites remains underexplored. Methods: In this work, we present the crystal structures of trastuzumab Fab and Fc domains site-specifically conjugated with a cleavable linker–payload. Results: Our findings suggest that pockets within both Fab and Fc regions may interact with and shield the linker portion of the conjugate. Conclusions: These insights highlight the previously underappreciated potential of structure-based design to drive the optimization of ADC linker chemistry and facilitate the co-design of bespoke linker–payloads tailored to individual antibody conjugation sites.

13 May 2026 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
RWRenjing Wang
Renjing Wang
THThu Ho
Thu Ho
AOAimie Ogawa
Aimie Ogawa
KWKartika Widjaja
Kartika Widjaja
ZBZachary Brown
Zachary Brown
JCJill E Chrencik
Jill E Chrencik
Gasdermin D (GSDMD) has been identified as a critical component of the inflammasome, an important intracellular signaling multi-protein complex. Abnormal activation of GSDMD has been linked to a variety of inflammatory diseases, including non-alcoholic steatohepatitis, inflammatory bowel disease and COVID-19, and has been linked to potential pathogenesis of septic shock. While small molecules have been identified to inhibit N-terminal domain (NTD) pore formation and membrane translocation, further clinical application of these molecules is currently limited due to narrow specificity. Here, we report a peptide from a structure-based computational screen that selectively inhibits caspase-dependent cleavage of GSDMD. We have determined the structure of the GSDMD–peptide complex, indicating that peptide binding is facilitated by negatively charged residues from the peptide and the hydrophobic exosite of the protein, inhibiting caspase binding and activation. The experimental data suggest the potential to target the exosite for therapeutic intervention.

26 May 2026 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
JCJill E Chrencik
Jill E Chrencik
HSHua-Poo Su
Hua-Poo Su
YLYacob Gomez Llorente
Yacob Gomez Llorente
RPRachel L. Palte
Rachel L. Palte
DKDaniel J. Klein
Daniel J. Klein
SGSandra B. Gabelli
Sandra B. Gabelli
Structural biology has fundamentally influenced pharmaceutical research and development at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, progressing from pioneering macromolecular crystallography in the 1980s to a fully integrated platform that today encompasses X-ray crystallography, cryo-electron microscopy, micro-electron diffraction and cryo-electron tomography. In this review, we present a comprehensive overview of how these complementary methods have advanced drug discovery across diverse therapeutic areas. We illustrate how atomic to cellular structural insights inform drug discovery and development, from target identification and validation, hit finding, lead identification through lead optimization and clinical progression. Furthermore, we describe how structural biology techniques aid in formulation strategies of antibodies and vaccines. Finally, we highlight the growing integration of ex situ and in situ approaches as a paradigm shift towards elucidating drug mechanisms in native cellular contexts, a transition poised to accelerate the discovery and development of next-generation therapeutics.